Philip A. van Damme
Founder at Stichting Sanammad
Philip A. van Damme active positions
Companies | Position | Start | End |
---|---|---|---|
Stichting Sanammad | Director/Board Member | 01/01/2009 | - |
Founder | 01/01/2009 | - | |
President | 01/01/2009 | - | |
Sanammad Pharmaceuticals BV | Director/Board Member | 01/01/2014 | - |
Founder | 01/01/2014 | - | |
President | 01/01/2014 | - |
Career history of Philip A. van Damme
Former positions of Philip A. van Damme
Companies | Position | Start | End |
---|---|---|---|
AXIM BIOTECHNOLOGIES, INC. | Director/Board Member | 01/05/2014 | 06/05/2020 |
Chief Tech/Sci/R&D Officer | 01/05/2014 | 06/05/2020 | |
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Director/Board Member | 01/01/2012 | - |
Chief Tech/Sci/R&D Officer | 30/07/2013 | - |
Training of Philip A. van Damme
University of Utrecht | Doctorate Degree |
Statistics
International
Netherlands | 5 |
United States | 2 |
Operational
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Miscellaneous | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
AXIM BIOTECHNOLOGIES, INC. | Health Technology |
Private companies | 3 |
---|---|
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Health Technology |
Stichting Sanammad | Miscellaneous |
Sanammad Pharmaceuticals BV |
- Stock Market
- Insiders
- Philip A. van Damme
- Experience